Mosińska Paula, Gabryelska Agata, Zasada Malwina, Fichna Jakub
Department of Biochemistry, Faculty of Medicine, Medical University of Łódź Łódź, Poland.
Department of Biochemistry, Faculty of Medicine, Medical University of ŁódźŁódź, Poland; Department of Cosmetic Raw Materials Chemistry, Faculty of Pharmacy, Medical University of ŁódźŁódź, Poland.
Front Pharmacol. 2017 Mar 14;8:126. doi: 10.3389/fphar.2017.00126. eCollection 2017.
The aim of cancer therapy is to eradicate cancer without affecting healthy tissues. Current options available for treating colorectal cancer (CRC), including surgery, chemotherapy or radiotherapy, usually elicit multiple adverse effects and frequently fail to completely remove the tumor cells. Thus, there is a constant need for seeking cancer cell-specific therapeutics to improve the course of cancer therapy and reduce the risk of relapse. In this review we elaborate on the mechanisms underlying the immunotherapy with dendritic cells (DCs) and cytokine-induced killer (CIK) cells, and summarize their effectiveness and tolerability available clinical studies. Finally, we discuss the up-to-date combinatorial adoptive anti-cancer immunotherapy with CIK cells co-cultured with DCs that recently showed encouraging efficacy and usefulness in treating malignant disease, including CRC.
癌症治疗的目的是根除癌症而不影响健康组织。目前可用于治疗结直肠癌（CRC）的方法，包括手术、化疗或放疗，通常会引发多种不良反应，且常常无法完全清除肿瘤细胞。因此，一直需要寻找针对癌细胞的治疗方法，以改善癌症治疗过程并降低复发风险。在本综述中，我们阐述了树突状细胞（DC）和细胞因子诱导的杀伤（CIK）细胞免疫治疗的潜在机制，并总结了现有临床研究中它们的有效性和耐受性。最后，我们讨论了最近在治疗包括CRC在内的恶性疾病中显示出令人鼓舞的疗效和实用性的、将CIK细胞与DC共培养的最新组合性过继性抗癌免疫治疗。
